Aerovate Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $13.25
- Today's High:
- $13.93
- Open Price:
- $13.47
- 52W Low:
- $11.13
- 52W High:
- $30.79
- Prev. Close:
- $13.33
- Volume:
- 52942
Company Statistics
- Market Cap.:
- $397.04 million
- Book Value:
- 4.557
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.68%
- Return on Equity TTM:
- -41.54%
Company Profile
Aerovate Therapeutics Inc had its IPO on 2021-06-30 under the ticker symbol AVTE.
The company operates in the Healthcare sector and Biotechnology industry. Aerovate Therapeutics Inc has a staff strength of 43 employees.
Stock update
Shares of Aerovate Therapeutics Inc opened at $13.47 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13.25 - $13.93, and closed at $13.79.
This is a +3.45% increase from the previous day's closing price.
A total volume of 52,942 shares were traded at the close of the day’s session.
In the last one week, shares of Aerovate Therapeutics Inc have slipped by -12.17%.
Aerovate Therapeutics Inc's Key Ratios
Aerovate Therapeutics Inc has a market cap of $397.04 million, indicating a price to book ratio of 4.5483 and a price to sales ratio of 0.
In the last 12-months Aerovate Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-59779000. The EBITDA ratio measures Aerovate Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aerovate Therapeutics Inc’s operating margin was 0% while its return on assets stood at -25.68% with a return of equity of -41.54%.
In Q1, Aerovate Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aerovate Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aerovate Therapeutics Inc’s profitability.
Aerovate Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -10.778. Its price to sales ratio in the trailing 12-months stood at 0.
Aerovate Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $124.39 million
- Total Liabilities
- $10.64 million
- Operating Cash Flow
- $15.38 million
- Capital Expenditure
- $16000
- Dividend Payout Ratio
- 0%
Aerovate Therapeutics Inc ended 2024 with $124.39 million in total assets and $0 in total liabilities. Its intangible assets were valued at $124.39 million while shareholder equity stood at $113.10 million.
Aerovate Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.64 million in other current liabilities, 2000.00 in common stock, $-104423000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $26.57 million and cash and short-term investments were $118.93 million. The company’s total short-term debt was $373,000 while long-term debt stood at $0.
Aerovate Therapeutics Inc’s total current assets stands at $120.57 million while long-term investments were $0 and short-term investments were $92.36 million. Its net receivables were $0 compared to accounts payable of $4.73 million and inventory worth $0.
In 2024, Aerovate Therapeutics Inc's operating cash flow was $15.38 million while its capital expenditure stood at $16000.
Comparatively, Aerovate Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $13.79
- 52-Week High
- $30.79
- 52-Week Low
- $11.13
- Analyst Target Price
- $33
Aerovate Therapeutics Inc stock is currently trading at $13.79 per share. It touched a 52-week high of $30.79 and a 52-week low of $30.79. Analysts tracking the stock have a 12-month average target price of $33.
Its 50-day moving average was $16.01 and 200-day moving average was $20.07 The short ratio stood at 12.86 indicating a short percent outstanding of 0%.
Around 24.5% of the company’s stock are held by insiders while 11038.1% are held by institutions.
Frequently Asked Questions About Aerovate Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.